LDL-receptor gene mutations and the hypocholesterolemic response to statin therapy

Clinical Genetics

Volumn 59, Issue 6, 2001, Pages 397-405

  Brorholt Petersen, Jens Uffe ^a   Jensen, H K ^a   Raungaard, B ^a   Gregersen, N ^a   Faergeman, O ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Drugs; Genetics; Hypercholesterolemia; Lipids; Pharmacology

Indexed keywords

CHOLESTEROL; FLUINDOSTATIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRYPTOPHAN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; HYPOTHESIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; POPULATION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; STATISTICAL ANALYSIS;

ADULT; AGED; BODY MASS INDEX; CHOLESTEROL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INDOLES; MALE; MIDDLE AGED; MUTATION; RECEPTORS, LDL; TREATMENT OUTCOME;

EID: 0034955485     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.2001.590604.x     Document Type: Article

References (41)

1. Familial hyper-cholesterolemia
2. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province
3. Mortality in treated heterozygous familial hyper-cholesterolaemia: Implications for clinical management
4. Update on low density lipoprotein receptor mutations
5. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia
6. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia
7. Influence of specific mutations at the LDL receptor gene locus on the response to simvastatin in familial hypercholesterolemia
8. Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia
9. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familialhypercholesterolemia
10. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia
11. Is responsiveness to lovastatin in familial hypercholesterolaemia heterozygotes influenced by the specific mutation in the low-density lipoprotein receptor gene?
12. Heterozygous familial hypercholesterolaemia: The influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment
13. Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia
14. Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations
15. The Trp23-stop and Trp66-Gly mutations in the LDL receptor: Common causes of familial hypercholesterolemia in Denmark
16. Functional characterization of two low density lipoprotein receptor gene mutations by fluorescence flow cytometric assessment of receptor activity in stimulated human T-lymphocytes
17. Strategies for the prevention of coronary heart disease: A policy statement of the European Atherosclerosis Society
18. Fluvastatin: A review of its pharmacology and use in the management of hypercholesterolaemia
19. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
20. Genotyping compared with protein phenotyping of the common apolipoprotein E polymorphism
21. Familial hypercholesterolemia and apolipoprotein E4
22. Apolipoprotein E polymorphism and plasma cholesterol response to probucol
23. Effects of probucol on plasma lipids and lipoproteins in familial hypercholesterolemic patients with and without apolipoprotein E4
24. Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia
25. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism
26. Apolipoprotein E phenotypes in familial hypercholesterolemia: Importance for expression of disease and response to therapy
27. Comparative study of lovastatin versus probucol in the treatment of hypercholesterolemia
28. When cells stop making sense: Effects of nonsense codons on RNA metabolism in vertebrate cells
29. The Lebanese allele at the low density lipoprotein receptor locus. Nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum
30. Two common low density lipoprotein receptor gene mutations cause familial hypercholesterolemia in Afrikaners
31. Two mutant low-density-lipoprotein receptors in Afrikaners slowly processed to surface forms exhibiting rapid degradation or functional heterogeneity
32. Effects of ML-236b (compactin) on sterol synthesis and low density lipoprotein receptor activities in fibroblasts of patients with homozygous familial hypercholesterolemia
33. Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia
34. Common low-density lipoprotein receptor mutations in the French Canadian population
35. Finnish type of low density lipoprotein receptor gene mutation (FH-Helsinki) deletes exons encoding the carboxy-terminal part of the receptor and creates an internalization-defective phenotype
36. The familial hypercholesterolemia (FH)-North Karelia mutation of the low density lipoprotein receptor gene deletes seven nucleotides of exon 6 and is a common cause of FH in Finland
37. Detection of allele-specific transcripts by the polymerase chain reaction (AST-PCR)
38. Genetic clues revise view of Japanese roots
39. mtDNA analysis reveals a major late Paleolithic population expansion from southwestern to northeastern Europe
40. Molecular background of the Finnish disease heritage